IPI 145

Product Name: IPI 145
CAS No.: 1201438-56-3
Chemical Name: IPI 145
Synonyms: Duvelisib;CS-680;IPI-14;IPI-145;IPI 145;IPI-145, >=98%;IPI-145 INK197;IPI 145 USP/EP/BP;IPI-145 (INK-1197);DUVELISIB (IPI-145)
CBNumber: CB32645143
Molecular Formula: C22H17ClN6O
Formula Weight: 416.86
MOL File: 1201438-56-3.mol

More

Less

IPI 145 Property

Melting point:: 205-206o C
Boiling point:: 757.8±60.0 °C(Predicted)
Density: 1.474±0.06 g/cm3(Predicted)
storage temp.: -20°C
solubility: Soluble in DMSO (up to at least 25 mg/ml)
form: White solid.
pka: 10.05±0.10(Predicted)
color: White
Stability:: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word: Danger
Hazard statements: H360May damage fertility or the unborn child

More

Less

N-Bromosuccinimide Price

Cayman Chemical

Product number: 16800
Product name: IPI-145
Purity: ≥98%
Packaging: 500μg
Price: $68
Updated: 2024/03/01

Cayman Chemical

Product number: 16800
Product name: IPI-145
Purity: ≥98%
Packaging: 1mg
Price: $121
Updated: 2024/03/01

Cayman Chemical

Product number: 16800
Product name: IPI-145
Purity: ≥98%
Packaging: 5mg
Price: $201
Updated: 2024/03/01

Cayman Chemical

Product number: 16800
Product name: IPI-145
Purity: ≥98%
Packaging: 10mg
Price: $335
Updated: 2024/03/01

TRC

Product number: I739400
Product name: IPI145
Packaging: 50mg
Price: $225
Updated: 2021/12/16

More

Less

IPI 145 Chemical Properties,Usage,Production

Description

Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor cross-linking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2?Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others.3,4?Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5?Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes

Uses

IPI 145 is an 1,2-dihydroisoquinolin-1(2H)-one derivative and has been developed as a modulator of PI3 kinase.

Definition

ChEBI: 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone is a member of isoquinolines.

brand name

Copiktra

General Description

Class: lipid kinase; Treatment: CLL, SLL, FL; Other name: INK1197, IPI145; Oral bioavailability = 42%; Elimination half-life = 4.7 h; Protein binding = 98%

Pharmacokinetics

The recommended dose of duvelisib is 25 mg twice daily, much lower than that of idelalisib (150 mg, bid). Duvelisib is rapidly absorbed, with a peak concentration after 1–2 h. Following the administration of 25 mg of duvelisib, the absolute bioavailability in healthy volunteers is 42%. It is eliminated with a short half-life of 4.7 h, thus requiring twice daily administration.

target

PI3Kγ/δ

IC 50

Metabolism

Duvelisib is primarily metabolized by CYP3A4 to give a monooxidation product, IPI-656, which has no pharmacologically relevant activity.

References

1) Winkler?et al.?(2013),?PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Response and Suppresses Activity in Autoimmune and Inflammatory Disease Models;?Chem. Biol.?20?1309 2) Dong?et al.?(2014),?IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells;?Blood?124?3583 3) Flinn?et al.?(2018),?Duvelisib, a novel dual inhibitor of PI3K-δ/γ, is clinically active in advances hematologic malignancies;?Blood?131?877 4) Faia?et al.?(2018),?The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib, shows preclinical synergy with multiple targeted therapies in hematologic malignancies;?PLoS One?13?e0200725 5) Davis?et al.?(2017),?Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ;?Cancer Res.?77?2607

IPI 145 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

IPI 145 Suppliers

Canada 1 China 147 India 2 United Kingdom 1 United States 20 Global 171

MedChemexpress LLC

Tel: 021-58955995
Fax: 609-228-5909
Email: sales@medchemexpress.cn
Country: United States
ProdList: 4861
Advantage: 58

AdooQ BioScience, LLC

Tel: +1 (866) 930-6790
Fax: +1 (866) 333-9607
Email: info@adooq.com
Country: United States
ProdList: 2782
Advantage: 58

Target molecule Corp.

Tel: 857-239-0968
Fax: 857-239-8801
Email: service1@targetmol.com
Country: United States
ProdList: 2559
Advantage: 60

Musechem

Tel: +1-800-259-7612
Fax: +1-800-259-7612
Email: info@musechem.com
Country: United States
ProdList: 4660
Advantage: 60

TargetMol Chemicals Inc.

Tel: +1-781-999-5354 +1-00000000000
Email: marketing@targetmol.com
Country: United States
ProdList: 32165
Advantage: 58

InvivoChem

Tel: +1-708-310-1919 +1-13798911105
Fax: 708-557-7486
Email: sales@invivochem.cn
Country: United States
ProdList: 6391
Advantage: 58

Cckinase, Inc.

Tel: +1 (732)236-3202
Email: sales@cckinase.com
Country: United States
ProdList: 2738
Advantage: 58

BOC Sciences

Tel: +1-631-485-4226
Fax: 1-631-614-7828
Email: inquiry@bocsci.com
Country: United States
ProdList: 19553
Advantage: 58

Aladdin Scientific

Tel: +1-+1(833)-552-7181
Email: sales@aladdinsci.com
Country: United States
ProdList: 57505
Advantage: 58

ApexBio Technology

Tel: --
Fax: --
Email: sales@apexbt.com
Country: United States
ProdList: 6251
Advantage: 58

NE Scientific

Tel: --
Fax: --
Country: United States
ProdList: 5030
Advantage: 55

Focus Biomolecules

Tel: --
Fax: --
Email: sales@focusbiomolecules.com
Country: United States
ProdList: 1284
Advantage: 58

Cayman Chemical Company

Tel: --
Fax: --
Email: cayman@caymanchem.com
Country: United States
ProdList: 6213
Advantage: 81

LC Laboratories

Tel: --
Fax: --
Email: custserv@lclabs.com
Country: United States
ProdList: 503
Advantage: 50

United States Biological

Tel: --
Fax: --
Email: chemicals@usbio.net
Country: United States
ProdList: 6214
Advantage: 80

Creative Enzymes

Tel: --
Fax: --
Email: info@creative-enzymes.com
Country: United States
ProdList: 6057
Advantage: 58

Matrix Scientific

Tel: --
Fax: --
Email: sales@matrixscientific.com
Country: United States
ProdList: 6632
Advantage: 80

Selleck Chemicals LLC

Tel: --
Fax: --
Email: info@selleckchem.com
Country: United States
ProdList: 824
Advantage: 60

ChemieTek

Tel: --
Fax: --
Email: info@chemietek.com
Country: United States
ProdList: 219
Advantage: 50

LKT Laboratories, Inc.

Tel: --
Fax: --
Email: info@lktlabs.com
Country: United States
ProdList: 2164
Advantage: 64

More

Less

View Lastest Price from IPI 145 manufacturers

Zhuozhou Wenxi import and Export Co., Ltd

Product: Duvelisib (IPI-145; INK1197) 1201438-56-3
Price: US $15.00-10.00/KG
Min. Order: 1KG
Purity: 99%+ HPLC
Supply Ability: Monthly supply of 1 ton
Release date: 2021-07-11

Zhuozhou Wenxi import and Export Co., Ltd

Product: Duvelisib (IPI-145; INK1197) 1201438-56-3
Price: US $15.00-10.00/KG
Min. Order: 1KG
Purity: 99%+ HPLC
Supply Ability: Monthly supply of 1 ton
Release date: 2021-07-09

Career Henan Chemical Co

Product: IPI 145 1201438-56-3
Price: US $5.00/KG
Min. Order: 1KG
Purity: 99%
Supply Ability: 1ton
Release date: 2019-09-03

1201438-56-3, IPI 145Related Search:

Silicone oil Zafirlukast Sunitinib Malate Oxaprozin Pioglitazone hydrochloride Calcium lactate Selumetinib MK-2206 2HCl Alpelisib (BYL719) CAL-101 Ibrutinib Ruxolitinib

IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197;DUVELISIB (IPI-145; INK1197)

CS-680

8-chloro-2-phenyl-3-[(1s)-1-(7h-purin-6-ylamino)ethyl]isoquinolin-1-one

IPI-145 (Duvelisib, INK1197)

IPI-145

IPI-145 (INK-1197)

IPI-145 INK197

8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone

Duvelisib

IPI-145, >=98%

Duvelisib (IPI-145, INK1197)

DUVELISIB (IPI-145)

1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-

8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone Duvelisib (IPI-145, INK1197)

Duvelisib INK 1197

IPI 145

IPI 145 (Duvelisib)

IPI-145, INK 1197, Duvelisib

IPI-145 INK197;DUVELISIB (IPI-145)

IPI-14

DUVELISIB (IPI-145, INK1197);IPI 145; IPI145

Duvelisib, 98%, a novel and selective PI3K δ/γ inhibitor

DUVELISIB, 1201438-56-3, DUVELISIB [USAN], SURECN153543, UNII-610V23S0JI, IPI145, CHEMBL3039502, MOLPORT-028-600-025

IPI 145 USP/EP/BP

IPI-145, INK197,Duvelisib

INK-1197,Phosphoinositide 3-kinase,IPI 145,IPI145,inhibit,Duvelisib,PI3K,INK 1197,Inhibitor

Dosulepin Impurity 3 (Dosulepin EP Impurity C)

1201438-56-3

201438-56-3

reference inhibitors

Inhibitors